Registry-listed formulations

tariquidar · mesh:C402343

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    67%(2 trials)

    Phase Distribution

    Phase 1
    1
    33%
    Phase 2
    2
    67%

    Phase Distribution

    1

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 2Efficacy & side effects
    2(66.7%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(3)

    Detailed Status

    Completed3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 11 (33.3%)
    Phase 22 (66.7%)

    Trials by Status

    completed3100%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_1

    Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

    NCT00011414
    completedphase_2

    PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

    NCT00082368
    completedphase_2

    Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

    NCT00069160

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT00011414Phase 1

    Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

    Completed
    NCT00082368Phase 2

    PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

    Completed
    NCT00069160Phase 2

    Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    3

    External References

    ChEMBL
    CHEMBL348475

    Names & Codes

    Research Codes

    XR 9576